Steven V. Edelman, MD Founder & Director, TCOYD

Dr. Edelman is a professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego and the director of the Diabetes Care Clinic VA Medical Center. He graduated as the valedictorian from the University of California at Davis Medical School, received his internal medicine training at the Internal Medicine Residency at the University of California–Los Angeles, and completed his endocrinology fellowship at the Joslin and Lahey Clinics in Boston, Mass., as well as a research fellowship at UCSD.

Dr. Edelman has strong interests in education and patient advocacy. He is the founder and director of Taking Control of Your Diabetes (TCOYD), a not-for-profit organization dedicated to informing and empowering people with diabetes to become actively involved in their own health care. TCOYD does this through live national conferences, local events, publications, online resources and our educational television series.

Dr. Edelman’s has written more than 200 articles and five books. He has won numerous awards for teaching and humanitarianism including the American Diabetes Association’s 2009 Outstanding Educator in Diabetes Award, and was recognized by San Diego Magazine as a Top Doctor several times. He is an active member of The Endocrine Society, the Juvenile Diabetes Foundation, the American Diabetes Association,the  American Association of Diabetes Educators, the Association of Clinical Endocrinologists, and the International Diabetes Federation.

CURRICULUM VITAE

Board Certification:
Internal Medicine (September 1986)
Diabetes, Endocrinology and Metabolism
Certified: November 1991
Re-certified: November 2001

Education/Employment:

2001 - present Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of California San Diego. Veterans Affairs Healthcare System, San Diego.

1995-2001 Associate Professor of Medicine, Division of Endocrinology and Metabolism, University of California San Diego. Veterans Affairs Healthcare System, San Diego.

1991-1995 Assistant Professor of Medicine, Division of Endocrinology and Metabolism, University of California San Diego.

1989-1990 Visiting Physician, Department of Medicine, Division of Endocrinology and Diabetes, Chaim Sheba Medical Center, Tel Hashomer, Israel.

1989-1990 Staff Physician, Portland Diabetes and Endocrinology Center, Portland, Oregon.

1989-1990 Clinical Assistant Professor, Department of Medicine, Division of Endocrinology and Metabolism, University of Oregon Center for Health Sciences, Portland, Oregon.

1987-1989 Research Fellowship in Diabetes and Metabolism, University of California, San Diego, California.

1986-1987 Fellowship in Endocrinology and Metabolism, The Lahey Clinic, Burlington, Massachusetts.

1985-1986 Clinical Fellowship in Diabetes and Metabolism, The Joslin Clinic, Boston, Massachusetts.

1982-1985 Resident in Internal Medicine, University of California Los Angeles - San Fernando Program, Sepulveda, California.

1978-1982 Doctor of Medicine, University of California at Davis.

1977-1978 Master of Science, Biology, University of California at Los Angeles, Los Angeles, California.

1973-1977 Bachelor of Science, Biology, University of California at Los Angeles, Los Angeles, California.

Academic Activities:

Director, Endocrine Fellowship Training Program, University of California San Diego and the Veterans Affairs Medical Healthcare System

Director, Clinical Clerkship Program, University of California San Diego and the Veterans Affairs Healthcare System

Director of the Diabetes Care Clinic VA Medical Center, San Diego, CA

UCSD School of Medicine Student Affairs Committee

2004 Board member of the California Chapter of AACE Board of Directors

Associate editor for Clinical Diabetes (ADA publication)

Committee Member, Professional Education Committee, American Diabetes Association

Medical Advisory Board, Diabetes Health, Kings Publishing, San Francisco, CA

Editorial Advisory Board, Endocrine Today, SLACK Incorporated, Thorofare, NJ

Journal Reviewer: Annals of Internal Medicine, Diabetes Monitor, Journal of Clinical Investigation, Journal of Clinical Endocrinology and Metabolism Diabetes Interviews, Diabetes Care, Diabetes, Diabetologia, Endocrine Practice, New England Journal of Medicine and Journal of Diabetes and its Complications.

Contributor to the Certification and Recertification Programs for the American Board to Internal Medicine

Research and ISP Advisor for graduate and medical students

Public Service

1995-present: Founder and Director of a 503c(3) non-profit organization TAKING CONTROL OF YOUR DIABETES (TCOYD), which promotes patient education, motivation and self-advocacy via a number of information portals (National conferences, publications, videocassettes, television, and community programs).

Academic Honors and Awards:

1977 Graduate cum Laude, University of California, Los Angeles

1977 University of California Los Angeles, Dean's Honor List

1978 University of California Regents Scholar

1982 Valedictorian, University of California, Davis Medical School

1982 Ad Hoc Judicial, Honors and Awards, and Admissions Committee, University of California, Davis Medical School

1985 National Commanders Award of the Disabled American Veterans, Sepulveda Veterans Affairs Medical Center, Los Angeles, CA

1994 Distinguished Alumnus Award, University of California Davis, Medical School.

1994 Chief Resident's Teacher of the Year Award University of California San Diego

1995 Citation of Excellence, Cal Aggi Alumni, Association

1996 Chief Resident's Teacher of the Year Award University of California San Diego

1997 House staff Teaching Award for Excellence: Honorable Mention University of California, San Diego

1999 Chief Resident's Teacher of the Year Award University of California San Diego

2000 House staff Teaching Award for Excellence Award University of California San Diego.

2001 House staff Teaching Award for Excellence Honorable Mention University of California San Diego.

2001 2001 Whittier Institutes Persistence Award for Public Service.

2001 2001 Healthcare Foundation of New Jersey's Humanism in Medicine Award.

2001 Chief Resident's Teacher of the Year Award University of California San Diego

2002 Chief Resident's Teacher of the Year Award University of California San Diego.

2002 House staff Teaching Award for Excellence Award University of California San Diego.

2003 San Diego Magazine Top Doctors in San Diego County award.

2004 San Diego Magazine Top Doctors in San Diego County award.

2006 Combined Health Agencies San Diego Chapter "Health Hero" Award

Activities:

Active Member:

The Endocrine Society
Association of Academic Professors
Juvenile Diabetes Foundation
American Diabetes Association
American Association of Diabetic Educators
American Physicians Fellowship
Insulin Pump Support Group
Association of Clinical Endocrinologists
American Society of Clinical Investigation
International Diabetes Federation


Teaching Experience:

2000-Present Director, Endocrine Fellowship Training Program, UCSD and VA Medical Center, San Diego, CA

1991-2000 Co-Director, Endocrine Fellowship Training Program, UCSD and VA Medical Center, San Diego, CA

1989-1991 Residency Education Staff, Good Samaritan Hospital, Portland, OR

1987-1989 Teaching Assistant, University of California, San Diego, Department of Medicine, Division of Endocrinology and Metabolism, San Diego, CA

1985-1987 Teaching Assistant, Harvard Medical School, Department of Medicine, Boston, MA

1977-1978 Teaching Assistant, Department of Human Physiology, University of Southern California, Los Angeles, CA

Publications:

1. Tuck ML, Edelman SV. Drug therapy: special concerns in the hypertensive diabetic. Mod Med. 11:48-54, 1985.

2. Edelman SV, Kosofsky E, Paul R, Kozak GP. Neuro-osteoarthropathy (charcot's joint) in diabetes mellitus following revascularization surgery. Arc Intern Med. 147:1504-1508, 1987.

3. Vignati L, Edelman SV. Replacement of pancreatic function through the use of mechanical or electronic devices. In: Organ Transplantation and Replacement. G.J. Cerilli, editor. J.B. Lippincott, Philadelphia, PA. 680-688, 1988. (book chapter)

4. Baron AD, Brechtel G, Wallace P, Edelman SV. Fasting decreases rates of non-insulin-mediated glucose uptake in man. J Clin Endocrinol Metab. 67:532-540, 1988.

5. Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites of non-insulin and insulin-mediated glucose uptake in humans. Am J Physiol. 255:E769-E774, 1988.

6. Baron AD, Brechtel G, Edelman SV. Effects of free fatty acids on ketone bodies on in vivo non-insulin-mediated glucose utilization and production in humans. Metabolism. 38:1056-1061, 1989.

7. Edelman SV, Witztum J. Hyperkalemia during treatment with HMG- CoA reductase inhibitor. New Engl J Med. 320:1219-1220, 1989.

8. Molina JM, Baron AD, Edelman SV, Brechtel G, Wallace P, Olefsky JM. Use of a variable tracer infusion method to determine glucose turnover in humans. Am J Physiol. 25(8):E16-E23, 1990.

9. Baron AD, Laakso M, Brechtel G, Hoit B, Watt C, Edelman SV. Reduced postprandial skeletal muscle blood flow contributes to glucose intolerance in human obesity. J Clin Endocrinol Metab. 70:1525-1533, 1990.

10. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest. 85:1844-52, 1990.

11. Edelman SV, Laakso M, Brechtel G, Wallace P, Olefsky JM, Baron AD. Kinetics of insulin-mediated and non-insulin-mediated glucose uptake in humans. Diabetes. 39(8):955-964, 1990.

12. Laakso M, Edelman SV, Olefsky JM, Brechtel G, Wallace P, Baron AD. Kinetics of in vivo muscle insulin-mediated glucose uptake in human obesity. Diabetes. 39(8):965-974, 1990.

13. Edelman SV. Intensive insulin therapy. Diabetes Forecast 44:40-43, 1991.

14. Baron AD, Laakso M, Brechtel G, Edelman SV. Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in non-insulin-dependent diabetic subjects: effects of insulin therapy. J Clin Invest. 87:1186-1194, 1991.

15. Baron AD, Laakso M, Brechtel G, Edelman SV. Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab. 73:637-643, 1991.

16. Henry RR, Edelman SV. Advances in treatment of type II diabetes mellitus in the elderly. Geriatrics. 47:24-30, 1992.

17. Saudek CD, Duckworth WC, Veterans Affairs Study Group. Edelman SV. The Department of Veterans Affairs implanted insulin pump study. Diabetes Care. 15:567-570, 1992.

18. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 41:1076-1083, 1992.

19. Duckworth WC, Saudek CD, Henry RR, and The Veterans Affairs Study Group. Edelman SV. Why intraperitoneal delivery of insulin with implantable pumps in NIDDM? Diabetes. 41:657-661, 1992.

20. Laakso M, Edelman SV, Brechtel, G Baron AD. Effects of epinephrine on insulin-mediated glucose uptake in whole body and leg muscle in humans: role of blood flow. Am J Physiol. 263:E199-E209, 1992.

21. Edelman SV. Diabetes mellitus: recent developments and clinical implications. In: Manual of Endocrinology and Metabolism. Norman Lavin, editor. Little, Brown and Company, Boston, MA. 581-586, 1994. (invit. chapter)

22. Edelman SV. The diabetes epidemic. In: Medical Section Proceedings of the American Council of Life Insurance. JG Pallas, editor. 1994.

23. Edelman SV, White D, Henry RR. Intensive insulin therapy for patients with type II diabetes. International Diabetes Monitor. 7(2):1-9, 1994.

24. Edelman SV and Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes: application, benefits and risks. Diabetes Review. 3:308-334, 1995.

25. Edelman SV. Impaired glucose tolerance: a precursor of NIDDM or a disease entity in itself? Diabetes News. 26:1-5, 1995.

26. Edelman SV, White D, Henry RR. Intensive insulin therapy for patients with type II diabetes. Current Opinion in Endocrinology and Diabetes. 2:333-340, 1995.

27. Reaven P, Herold DA, Barrett JE, Edelman SV. Effects of vitamin E on susceptibility of LDL and LDL subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care. 18(6):807-816, 1995.

28. Henry RR, Edelman SV. Diabetes mellitus in adults. In: Conn's Current Therapy. Conn HF et al, editors. 28:522-530, 1995. (invit. chapter)

29. DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Edelman SV. Implementation of screening and staging of relatives. Transplantation Proceedings. 27(6):3377, 1995.

30. Edelman SV. Glycemic control and complications in type II diabetes: design of a feasibility trial: summary and commentary. Diabetes Spectrum. 9(1):47-50, 1996.

31. Edelman SV. New orally administered antihyperglycemic agents for the management of patients with type II diabetes and the syndrome of insulin resistance. Endocrine Practice. 2(4):271-275, 1996.

32. Edelman SV. Management of patients with diabetes by nurses with support subspecialists: summary and commentary. Diabetes Spectrum. 9(3):178-180, 1996.

33. Edelman SV. New oral antidiabetic agents for the prevention and management of NIDDM. International Diabetes Monitor. 8(4):1-8, 1996.

34. Edelman SV and Henry RR. Intensive insulin treatment for patients with type II diabetes: a fundamental and clinical text. In: Diabetes Mellitus. D LeRoith, SI Taylor, JM Olefsky, editors. Lippincott -Raven JB, Philadelphia, PA. p. 647, 1996. (invit. chapter)

35. Saudek CD, Duckworth WC, Giobbie-Hurder A, Henderson WG, Henry RR, Kelley DE, Edelman SV, Zieve F, Adler RA, Anderson JW, Anderson RJ, Hamilton BP, Donner TW, Kirkman MS, Morgan NA, Department of Veterans Affairs. Implantable insulin pump vs. multiple dose insulin in the treatment of non-insulin-dependent diabetes mellitus: a randomized clinical trial. JAMA. 276:1322-1327, 1996.

36. Kelley DE, Henry RR, Edelman SV, Veterans Affairs Implantable Insulin Pump Study Group. Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Diabetes Care. 19(11):1237-1242, 1996.

37. Edelman SV, Kartun K, Nadeau DA, Prince MJ. Clinical case studies in diabetes: pearls and pitfalls. A focus on NIDDM. Volume 1. Alain D. Baron, editor. Clinical Communications Inc., Greenwich, CT. pages 1-29, 1996. (pamphlet)

38. Edelman SV, Kartun K, Prince MJ, Zimmerman BR. Clinical case studies in diabetes: pearls and pitfalls. A focus on NIDDM. Volume 2. Alain D. Baron, editor. Clinical Communications Inc., Greenwich, CT. pages 1-33, 1996. (pamphlet)

39. Edelman, SV. Troglitazone: a new and unique oral anti-diabetic agent for the treatment of type II diabetes and the insulin resistant syndrome. Clinical Diabetes. 15(2):60-65, 1997.

40. Edelman SV, Henry RR. Non-insulin-dependent diabetes mellitus. In: Current Therapy in Endocrinology and Metabolism. Sixth Edition. CW Bardin, editor. Mosby-Year Book Inc. pages 430-438, 1997. (book chapter)

41. Edelman SV, Henry RR. Diagnosis and management of type II diabetes. First Edition. Professional Communications Inc., Greenwich, CT. 223 pages, 1997. (book)

42. Buse JB, Edelman SV, Knudson. Clinical case studies in diabetes: pearls and pitfalls. A focus on NIDDM. Volume 3. Alain D. Baron, editor. Clinical Communications Inc., Greenwich, CT. pages 1-33, 1997. (pamphlet)

43. Edelman SV, Kirkman SM, Zimmerman BR. Clinical case studies in diabetes: pearls and pitfalls. A focus on NIDDM. Volume 4. Alain D. Baron, editor. Clinical Communications Inc., Greenwich, CT. pages 1-36, 1997. (pamphlet)

44. Edelman SV, Henry RR. Diagnosis and management of type II diabetes. Second Edition. Professional Communications Inc., Greenwich, CT. 239 pages, 1997. (book)

45. Bagdade JD, Kelly DE, Henry RR, Eckel RH, Ritter MC, for the Department of Veterans Affairs Implantable Insulin Pump Study Group. Edelman SV. Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipase activities in NIDDM. Diabetes. 46:414-420, 1997.

46. Edelman SV. Type II diabetes. In: Advances in Internal Medicine. John Baxter, editor. Mosby-Year Book Inc. 43:449-500, 1997. (book chapter)

47. Edelman SV, Kruger DF. A new look at glucose control: the case for therapy with insulin and an amylin analog. Practical Diabetology. 16(4):9-14, 1997.

48. Edelman SV. Prescribing oral antidiabetic agents: general considerations. Clinical Diabetes. 16(1):37-42, 1998.

49. Edelman SV. Prevention, early detection, and aggressive management of diabetic kidney disease. Clinical Diabetes. 16(2):77-80, 1998.

50. The Veterans Affairs Implantable Insulin Pump Study Group. Edelman, SV. The Veterans Affairs implantable insulin pump study: effects on cardiovascular risk factors. Diabetes Care. 21(10):1596-1602, 1998.

51. Harati, Edelman SV, Greene, Raskin, Cornblath, Donofrio, Swenson, Kamin. Efficacy of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 50(6):1842-1846, 1998.

52. Edelman SV. The importance of glucose control. Med Clin North Am. 82:665-672, 1998. (book chapter)

53. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Primary Care Clinics of North America. 26:771-789, 1998. (book chapter)

54. Edelman SV. A practical approach to combination therapy: daytime oral agent(s) and bedtime NPH insulin. Clinical Diabetes. 17(3):100-102, 1999.

55. The Diabetes Prevention Program Research Group, Edelman SV. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 22(4):623-634, 1999.

56. Edelman SV, Henry RR. Diagnosis and management of type II diabetes. Third Edition. Professional Communications, Inc., Greenwich, CT. 1999. (book)

57. Edelman SV. Taking control of your diabetes: a patient oriented book on diabetes. Professional Communications Inc., Greenwich, CT. 275 pages, 2000. (book)

58. Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clinical Diabetes. 18(2):80-82, 2000.

59. Edelman SV. Insulin pump therapy: a practical tool for treating persons with type 1 and insulin-requiring type 2 diabetes. In: Medical Management of Diabetes Mellitus. Marcel Dekker, Inc. pages 309-323, 2000. (invit. chapter)

60. Edelman SV, Callahan P, Deeb L. Multisite evaluation of a new diabetes self-test for glucose and glycated protein (fructosamine). Diabetes Technol Ther. 2(2):231-236, 2000.

61. Mudaliar S, Edelman SV. Intensive insulin therapy for patients with type 2 diabetes mellitus. In: Diabetes Mellitus - A Fundamental and Clinical Text. Second Edition. D LeRoith, SI Taylor, JM Olefsky, editors. J.B. Lippincott -Raven, Philadelphia, PA. Chapter 83, pages 811-836, 2000. (book chapter)

62. Chu NV, Edelman SV. Quality of life in tightly controlled type 2 diabetics. International Diabetes Monitor. 12(2):15-16, 2000.

63. Wolosin JD, Edelman SV. Diabetes and the gastrointestinal tract. Clinical Diabetes. 18(4):148-151, 2000.

64. The Diabetes Prevention Program Research Group. Edelman SV. Baseline characteristics of the randomized cohort. Diabetes Care. 23(11):1619-1629, 2000.

65. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 14:65-70, 2000.

66. Mather K, Laakso M, Edelman SV, Hook G, Baron A. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab. 279:E1264-E1270, 2000.

67. The Diabetes Prevention Program Study Group. Edelman SV. The diabetes prevention program baseline characteristics of the randomized cohort. Diabetes Care. 23(11):1619-1629, 2000.

68. Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP, The Diabetes Prevention Trial-Type 1 Study Group. Edelman SV. Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the diabetes prevention trial-type 1. J Clin Endocrinol Metab. 85:1255-1260, 2000.

69. Greenbaum CJ, Cuthbertson D, Krischer JP, The Diabetes Prevention Trial of Type 1 Diabetes Study Group. Edelman SV. Type 1 diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes. 50:470-476, 2001.

70. Plodkowski RA and Edelman SV. Pre-surgical evaluation of diabetic patients. Clinical Diabetes. 19(2):92-94, 2001. (invit. article)

71. Pitzer KR, Desai S, Dunn T, Edelman SV, Jayalakshmi Y, Kennedy J, Tamada JA, Potts RO. Detection of hypoglycemia with the GlucoWatch Biographer. Diabetes Care. 24:881-885, 2001.

72. Kim RP, Edelman SV, Musculoskeletal complications of diabetes mellitus. Clinical Diabetes. 19(3):132-135, 2001.

73. Gilbert H, Edelman SV. Randomized trial of fructosamine home monitoring in patients with diabetes. Eff Clin Pract. Vol 1-0251, 2001.

74. Del Prato S, Edelman SV, Garg, SK. Current topics in diabetes mellitus CME. Medscape Diabetes & Endocrinology Treatment Updates, 4/5 of 60. Release date June 21, 2001. http://diabetes.medscape.com/Medscape/endocrinology.

75. Edelman SV. Watching your glucose with the GlucoWatch. Diabetes Technol Ther. 3(2):283-284, 2001.

76. Edelman SV. Does measuring fructosamine help patients with diabetes? Eff Clin Pract. 4(4):189-190, 2001.

77. Bremer T, Edelman SV, Gough DA. Benchmark data from the literature for evaluation of new glucose sensing technologies. Diabetes Technol Ther. 3(3):409-417, 2001.

78. Edelman SV, Bell JM, Serrano RB, Kelemen D. Home testing of fructosamine improves glycemic control in patients with diabetes. Endocr Pract. 7(6):454-458, 2001.

79. Chau D and Edelman SV. Clinical management of diabetes in the elderly. Clinical Diabetes. 19(4):172-175, 2001.

80. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 30(4):935-982, 2001.

81. Chu N, Edelman SV. Diabetes and erectile dysfunction. Clinical Diabetes. 19(1):45-47, 2001.

82. Plodkowski RA and Edelman SV. What is the relation between hyperinsulinemia and atherosclerosis? Medscape: Diabetes and Endocrinology. August 2001. http://www.medscape.com/viewarticle/4124021

83. Plodkowski RA and Edelman SV. Cost effectiveness of tightly controlled type 2 diabetes. International Diabetes Monitor. 13:11-14, 2001.

84. Plodkowski RA and Edelman SV. Diagnosing the cardiovascular multiple metabolic syndrome. Medscape: Diabetes and Endocrinolgy. August 2001. http://www.medscape.com/viewarticle/412377.

85. Del Prato, S, Edelman, SV, Garg SK. Current topics in diabetes mellitus. Medscape: Diabetes and Endocrinology Treatment Updates. 2001. http://www.medscape.com/Medscape/endocrinology/ TreatmentUpdate/2001/tu01/public/toc-tu01.html. 2001.

86. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH, Wilson DM, Wolfsdorf J, The Diabetes Prevention Trial-Type 1 Study Group. Edelman SV. First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J Pediatr. 138:244-249, 2001.

87. Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators. Edelman SV. Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the diabetes prevention trial-type 1. Diabetes. 50(8):1735-1740, 2001.

88. Plodkoswski RA and Edelman SV. Management of new-onset type 2 diabetes in patients presenting to an urgent-care or emergency-room setting. Medscape: Diabetes and Endo Ask the Experts. March 2002. http://www.medscape.com/viewarticle/428857 (online invit. article)

89. Plodkowski RA and Edelman SV. The state of insulin pump therapy-2002. Current Opinion in Endocrinology and Diabetes. 9(4):329-337, 2002.

90. Chu N, Edelman SV. Erectile dysfunction and diabetes. Curr Diab Rep. 2(1):60-66, 2002.

91. Diabetes Prevention Program Research Group. Edelman SV. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346(6):393-403, 2002.

92. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second b-cell hormone. Diabetes Technol Ther. 4(2):175-189, 2002.

93. Chau DL, Edelman SV. Osteoporosis and diabetes. Clinical Diabetes. 20(3):153-157, 2002.

94. Edelman SV, Henry RR. Diagnosis and management of type 2 diabetes. Fifth Edition. Professional Communications, Inc., Greenwich, CT. 288 pages, 2002. (book)

95. Edelman SV, Kim D. Diabetes mellitus: recent developments and clinical implications. In: Manual of Endocrinology and Metabolism. Third Edition. Norman Lavin, editor. Lippincott Williams and Wilkins. 2002. (book chapter)

96. The Diabetes Prevention Program Research Group. Edelman SV. The diabetes prevention program recruitment methods and results. Control Clinical Trial. 23(2):157-171, 2002.

97. The Diabetes Prevention Program Research Group. Edelman SV. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 40:679-686, 2002. 98. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Edelman SV. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 346:1685-1691, 2002.

99. Sarno MJ, Bell J, Edelman SV. Pharmacokinetics and glucodynamics of rapid, short, and intermediate acting insulins: a randomized, controlled trial comparing jet injection to needle syringe. Diabetes Technol Ther. 4(6):863-866, 2002.

100. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz DA, Palmer JP, Eisenbarth GS, The Diabetes Prevention Trial-Type 1 Study Group. Edelman SV. Screening strategies for the identification of multiple antibody positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab. 88:103-108, 2003.

101. M. Chandran, Edelman SV. Have insulin, will fly: diabetes management during air travel and time zone adjustment strategies. Clinical Diabetes. 21(2): 82-85, 2003.

102. Tabibiazar, Edelman SV, Ramin. Silent ischemia in people with diabetes: a condition that must be heard. Clinical Diabetes 21(1):5-9, 2003.

103. The Diabetes Prevention Program Research Group. Edelman SV. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 26(4):977-980, 2003.

104. Edelman SV, Chau D, Chandran M. Osteoporosis and diabetes. Curr Diab Rep. 3(1):37-42, 2003.

105. Chandran M, Neelima VC, Edelman SV. Gastrointestinal disturbances in diabetes. Curr Diab Rep. 3(1):43-48, 2003.

106. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S., Edelman SV, Henry R, Maisel A. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 26(7):2081-2087, 2003.

107. Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, Henderson W, participants of the VA Cooperative Study of Glycemic control and Complications in Diabetes Mellitus Type 2. Edelman SV. Design of the cooperative study on glycemic control ad complications in diabetes mellitus type 2. J Diabetes Complications. 17(6):314-322, 2003.

108. Chau DL, Goldstein-Fuchs J, and Edelman, SV. Clinical decision making: osteoporosis among patients with diabetes: an overlooked disease. Diabetes Spectrum. 16(3):176-182, 2003.

109. Molitch M, Fujimoto W, Hamman RF, Knowler WC, for the Diabetes Prevention Research Group. Edelman SV. The diabetes prevention program and its global implications. J Am Soc Nephrol. 14:S103-S107, 2003.

110. The Diabetes Prevention Program Research Group. Edelman SV. Within trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 26(9):2518-2523, 2003.

111. Edelman, SV. The Role of the Thiazolidinediones in the Practical Management of patients with Type 2 Diabetes and Cardiovascular Risk Factors. Reviews in Cardiovascular Medicine. 4(5): 51-59, 2003.

112. Edelman, SV. BNP Levels to Screen for Left Ventricular Dysfunction. Curr. Diab. Rep., 2004; 4(1): 39-40.

113. Firestone DN, Jimenez-Briceno L, Reimann JO, Talavera GA, Polonsky WH, Edelman SV. Predictors of diabetes-specific knowledge and treatment satisfaction among Costa Ricans with type 2 diabetes. Diabetes Educ. 30(2):1-25, 2004.

114. Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 27(3):734-738, 2004.

115. Plodkowski RA and Edelman SV. Insulin pump therapy in the management of diabetes. Contemporary Endo: Hormone Replacement Therapy. In press.

116. Kaufman FR, Farkin-Mervis LE, Ricker A, Wherrett D, The Diabetes Prevention Trial-Type 1 Study Group. Edelman SV. Recruitment of subjects into the diabetes prevention trial-type 1: strategies and progress report (1994-2000). Submitted.

117. Garg, S.K., Schwartz, Sherwyn, Edelman, S.V., Glucose Profiles in Patients Implanted with a Real-Time, Long-Term, Glucose Sensor. The 63rd Scientific Sessions of the American Diabetes Association. 2003.

118. Bhalla, M.A., Chiang, A., Epshteyn, V.A., Kazanegra, R., Bhalla, V., Clopton, P., Krishnaswamy, P., Morrison, L.K., Chiu, A., Gardetto, N., Mudaliar, S., Edelman, S.V., Henry, R.R., Maisel, A.S. Prognostic role of b-type natriuretic peptide levels in patients with type 2 diabetes. J Amer Coll Cardiol. 44(5):1047-1052. 2004.

119. Davis, Trent; Edelman, S.V., Insulin Therapy in Type 2 Diabetes. Med Clinic N Am 88: 865-895, 2004.

120. Edelman, SV, Hypoglycemia Unawareness, the Split-Mix Regimen, and Insulin Glargine Conversion in a Patient with Long-standing Type 1 Diabetes. Southern Medical Journal : E04-01. Vol 97. 2004.

121. The Diabetes Prevention Program Research Group, Edelman, SV, Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants. Obesity Research 2004; 12:1426-1434.

122. Edelman, SV, Morello, CM; Hypoglycemia Unawareness and Type 1 Diabetes. Southern Medical Journal

123. Ciaraldi, TP, Mudaliar, S, Barzin, A, Macievic, JA, Edelman, SV, Soo Park, K, Henry, RR. Skeletal Muscle Glut1 Transporter Protein Expression and Basal Leg Glucose Uptake are Reduced in Type 2 Diabetes. J Clin Endocrinol Metab. 90(1): 352-358. 2005.

124. The Diabetes Prevention Program Research Group, Edelman, SV, Strategies to Identify Adults at High Risk for Type 2 Diabetes. Diabetes Care 2005; 28:138-144.

125. The Diabetes Prevention Program Research Group, Edelman, SV, Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program. Diabetes. 54:1150-1156, 2005.

126. The Diabetes Prevention Program Research Group, Edelman, SV, Depression Symptoms and Antidepressant Medicine Use in Diabetes Prevention Program Participants. Diabetes Care 2005;28:830-837.

127. Orchard, TJ, Temprosa, M, Goldberg, R, Haffner, S, Ratner, R, Marcovina, S; for the Diabetes Prevention Program Research Group, SV Edelman. The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial. Ann Int Med 2005;142(8):611-619.

128. The Diabetes Prevention Program Research Group. Edelman, SV, Intensive lifestyle and metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes May 2005;54(5):1566-1572.

129. Edelman, SV, Postprandial Glucose is Important in Attaining Total Glycemic Control. Diabetic Microvascular Complications Today May/June 2005; 38-44.

130. The Diabetes Prevention Program Research Group. Edelman SV, Effects of Oral Insulin in Relatives of Patients with Type 1 Diabetes. Diabetes Care 2005;28:1068-1076.

131. The Diabetes Prevention Program Research Group. Edelman, SV, Ethnicity, Race and Baseline Retinopathy Correlates in the Veterans Affairs Diabetes Trial. Diabetes Care 2005;28(8):1954-1958.

132. The Diabetes Prevention Program Research Group. Edelman, SV, Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program. Effects of Lifestyle Intervention and Metformin. Diabetes 2005;54:2404-2414.

133. Bergenstal, RM, Johnson, Anderson RL, Edelman SV, Kendall DM. Impact of a One-Day Diabetes Education Program on Glycemic Control. Diabetes 2005;54(Suppl 2):935P.

134. Edelman SV, Polonsky WG, Beh G. Changes in Self-Care Behavior and Improved Glycemic Control in People with Diabetes after Attending an Intensive Education and Motivational Conference. Diabetes 2005;54(Suppl 2):299-OR.

135. The Diabetes Prevention Program Research Group. Edelman, SV, Lipid, Lipoproteins, C-reactive protein, and Hemostatic Factors at Baseline in the Diabetes Prevention Program. Diabetes Care 2005; 28:2472-2479.

136. Polonsky, WH, Fisher, L, Guzman, S, Villa-Caballero L, Edelman, SV, Psychological Insulin Resistance in Patients with Type 2 Diabetes: The Scope of the Problem. Diabetes Care. 28(10):2543-5, October 2005.

137. Edelman, SV, Incretins: What Does the Future Hold? Diabetes Technology & Therapeutics October 2005; 809-812.

138. Edelman, SV Does a Subject-Administered Titration Algorithn of Insulin and Glargine Improve Glycemic Control? Nature Clinical Practice Endocrinology & Metabolism February 2006. (Accepted for Publication).

139. The Diabetes Prevention Program Research Group. Lifestyle Intervention is Associated With Lower Prevalence of Urinary Incontinence. Edelman, SV, Diabetes Care 2006;29:385-390.

140. Plodkowski, RA, Edelman, SV, Physiologic Insulin Replacement with Continuous Subcutaneous Insulin Infusion: Insulin Pump Therapy. Clinical Diabetes 2006; 429-441.

141. The Diabetes Prevention Program Research Group. An Update on the Diabetes Prevention Program. Edelman, SV, Endocr Pract 2006;12 (Suppl 1):20-24.

142. The VADT Investigators. Control of Cardiovascular Risk Factors in the Veterans Affairs Diabetes Trial in Advanced Type 2 Diabetes. Edelman, SV, Endocr Pract 2006;12(Suppl 1):85-88.

143. Morello, C, Edelman, SV, Exenatide: A Novel Treatment Approach for Patients with Type 2 Diabetes. Practical Diabetology March 2006, 25(1): 6-18.

Monographs

1. Baron AD, Gavin JR, Lebovitz HE. Spotlight on Diabetes. SV Edelman, editor. Clinical Communications Inc., Greenwich, CT. 1989. (CD-ROM)

2. Edelman SV. Physiology of Glycemic Control. Oxford Clinical Communication, Inc., Amylin Pharmaceuticals, 1996.

3. Edelman SV. Diabetes - A Disease in Need of Greater Control. Oxford Clinical Communication, Inc., Amylin Pharmaceuticals, 1996.

4. Edelman SV. Diagnosis and Management of Type II Diabetes, First Edition. Professional Communication, Inc., 1997.

5. Edelman SV, Henry RR. Diagnosis and Management of Type II Diabetes, Second Edition. Professional Communications Inc. 1997.

6. Edelman SV. Postprandial Hyperglycemia: Implications For Type 2 Diabetes. Pharmedica Communications, Inc., 1997.

7. Edelman SV. Monograph: The Role of Troglitazone and the Clinical Management of Type 2 Diabetes and the Metabolic Syndrome. Sudler and Hennesee Inc., 1998.

8. Edelman SV. CD-ROM: Spotlight on Diabetes. Clinical Communications Inc., 1998.

9. Edelman SV. Other Complications: Clinical Trials Report. Curr Diabetes Rep, 2(1):47-66, 2002. 10. Edelman SV and Chu Neelima. Other Complications: Clinical Trials Report. Curr Diabetes Rep, 3(1):35-36, 2003

11. Edelman SV, Chandran Manju and Chu, Neelima. Gastrointestinal Disturbances in Diabetes. Curr Diabetes Rep, 3(1): 43-48, 2003

12. Edelman, SV, The Importance of Durable Glycemic Control in Type 2 Diabetes. Interactive Network for Continuing Education, 2002.

13. Edelman, SV, Mudaliar, Sunder and Riddle, Matthew C., Advances in Insulin Therapy: New Approaches to the Management of Type 2 Diabetes Mellitus. Medical Education Group LLC, 2004.

14. Edelman, SV. Case Study: A Patient with Type 2 Diabetes and Glucose Toxicity. Medical Education Group LLC, 2004.

15. Edelman, SV, Davidson, Jaime A. and Kendall, David M. The Role of Postprandial Glucose and Oral Antidiabetic Agents in the Management of Type 2 Diabetes Mellitus. MediKinetics, 2004.

16. Edelman, SV, Intensive Therapy with Inhaled Insulin in Patients with Type 2 Diabetes. International Diabetes Monitor, (Vol 17), 2005

17. Edelman, SV, LeRoith, Derek, editors, Insulin: A Clinical Journal for Primary Care (Vol 1. No. 1) January 2006.

Published Case Presentation

1. Edelman SV. Case Study: A 50 Year Old Man With Diabetes Fever and Metabolic Acidosis: Classification and Treatment. Clinical Diabetes 16(1):19-20, 1998.

Magazine Health Column

1. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, July 2004.

2. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, August 2004.

3. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, September 2004.

4. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, November 2004.

5. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, December 2004.

6. Edelman, SV, My TCOYD Newsletter. Volume 11, 4th Quarter 2004.

7. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, January 2005.

8. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, March 2005.

9. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, May 2005.

10. Edelman, SV, Taking Control of Your Diabetes. Diabetes Health, June 2005.

11. Edelman, SV, Practical Advice for Patients on Symlin Therapy, Diabetes Health, June 2005.

Letters to the Editor

1. Edelman, SV, Hypoglycemia Unawareness and Type 1 Diabetes. Southern Medical Journal, November 2004.

2. Edelman, SV, Thiazolidinediones. New England Journal of Medicine, 352; 2, January 2005.

Abstracts:

1. Molina JM, Baron AD, Edelman SV, Olefsky JM. Variable tracer infusion rate improves determination of glucose turnover in man. Clin Res. 36:151A, 1988.

2. Edelman SV, Brechtel G, Wallace P, Baron AD. Role of plasma flow to determine rates of in vivo insulin mediated glucose uptake. Clin Res. 36:151A, 1988.

3. Edelman SV, Wallace P, Baron AD. Insulin decreases the Km and increases the Vmax for in vivo muscle glucose uptake. Diabetes. 37 (Suppl):90A, 1988.

4. Laakso M, Edelman SV, Brechtel G, Baron AD. Kinetics of in vivo muscle glucose uptake in obesity are characterized by normal Km and reduced Vmax. Diabetes. 37 (Suppl):14A, 1988.

5. Edelman SV, Laakso M, Baron AD. Kinetics of in vivo muscle glucose uptake in non-insulin dependent diabetics are characterized by reduced capacity (Vmax) and low affinity (high Km). Clin Res. 37:128A, 1989.

6. Hoit B, Edelman SV, Laakso M, Watt C, Baron AD. Postprandial hemodynamics: role of insulin sensitivity. Clin Res. 37:1284, 1989.

7. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased insulin mediated glucose uptake (IMGU) in human obesity is largely due to reduced plasma flow (PF) to insulin sensitive tissues. Diabetes. 38 (Suppl):68A, 1989.

8. Edelman SV, Laakso M, Baron AD. Kinetics of in vivo muscle glucose uptake in type II diabetes are characterized by reduced capacity (Vmax) and low affinity (high Km). Diabetes. 39 (Suppl):67A, 1990.

9. Baron AD, Laakso M, Brechtel G, Edelman SV. Mechanisms of insulin resistance (IR) in insulin dependent diabetics (IDDM). A major role for reduced skeletal muscle blood flow. Diabetes. 39 (Suppl):86A, 1990.

10. Laakso M, Edelman SV, Brechtel G, Baron AD. Mechanism of epinephrine (Epi) induced insulin resistance (IR) in man. Diabetes. 39 (Suppl):22A, 1990.

11. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased insulin mediated glucose uptake (IMGU) in non-insulin-diabetes mellitus (NIDDM): role of blood flow. Diabetes. 40 (Suppl):100A, 1991.

12. Anderson JW, Edelman SV, Johnson NL, Duckworth WC, Saudec CD, The Implantable Insulin Pump Study Group. Glycemic control, insulin doses and weight changes with implantable insulin pump study. Diabetes. 42 (Suppl 1): 1993.

13. Edelman SV, Johnson N, Saudek CD, and the DAV Implantable Insulin Pump Study Group. A novel multi-center randomized clinical trial comparing intraperitoneal (IP) to subcutaneous (SC) insulin administration in patients with NIDDM: baseline characteristics. Diabetes. 42 (Suppl 1): 1993.

14. Edelman SV. Preliminary evaluation of a novel real-time blood glucose monitor. Diabetes. (Suppl):160A, 1994.

15. Veterans Affairs Study Group, VAMC Hines, IL. Veterans Affairs Implantable Insulin Pump Study 344A. Edelman SV. Mean glycemia and hypoglycemia. Diabetes. (Suppl):61A, 1994.

16. Veteran Affairs Study Group. Veterans Affairs Implantable Insulin Pump Study 344A. Edelman SV. Study design, baseline characteristics. Diabetes. (Suppl):61A, 1994.

17. Veterans Affairs Study Group, Chicago, IL. Veterans Affairs Implantable Insulin Pump (IIP) Study 344A. Edelman SV. Comparison of effects of implantable pumps and multiple insulin injections on metabolic and physiological parameters. Diabetes. (Suppl):61A, 1994.

18. Polonsky WH, Boswell SL, Edelman SV. Physician attributions concerning regimen adherence in diabetes. Diabetes. 45 (Suppl 2):14A, 1996.

19. Baloga JM, Edelman SV. Use of a real-time glucose sensor (VIA model 121) for glucose clamp studies. Diabetes. 45 (Suppl 2):142A #519, 1996.

20. Baloga JM., Edelman SV. Evaluation of a real-time glucose sensor (VIA model 121) for use during glucose clamp studies. J Investig Med. 44(1):129A, 1996.

21. Yu A, Wu PS, Edelman. SV. The natural history of non-insulin dependent diabetes mellitus in a Filipino migrant population. In: 3rd International Diabetes Federation, Western Pacific Regional Congress, p. 84, Hong Kong, September 25-28, 1996.

22. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblatt D, Sachdeo R, TPS DN Study Group. A double-blind placebo-controlled trial of tramadol for the pain of diabetic peripheral neuropathy. Submitted to the International Symposium on Diabetic Neuropathy: July 1997. J Peripher Nerv Syst. 2:270, 1997.

23. Baxi SC, Wu P, Bactad E, Edelman SV. The prevalence of thyroid disorders in type 2 diabetes mellitus. Diabetes. 46 (Suppl 1):323A, 1997.

24. Baxi SC, Knudson P, Edelman SV. A novel and simplified approach to insulin therapy in obese subjects with type 2 diabetes. Diabetes. 46 (Suppl 1):289A, 1997.

25. Mata, JE, Baloga J, Edelman SV. Clinical use of a continuous blood glucose monitoring system to reduce hospital stay for patients with poorly controlled diabetes. Diabetes. 46 (Suppl 1):152A, 1997.

26. Lucisano JY, Edelman SV, Quinto BD, Wong DK. Development of a biosensor-based, patient-attached blood glucose monitoring system. Proc Am Chem Soc. 76:256, 1997.

27. Buse J, Edelman SV, Neumann C. Precose resolution of optimal titration to enhance current therapies (P.R.O.T.E.C.T.) study: experience in patients with type II diabetes. Diabetes. 46 (Suppl 1):99A, 1997.

28. Lowry KA, Konzem SL, Edelman SV. Description of a primary care pharmacist role in the management of type I and type II diabetes. International Pharmaceutical 34:21 abstract 3412288, 1997.

29. Serrano RB, Champaigne N, Edelman SV. Changing patient behavior towards self-care through intensive education, motivation, and self-advocacy: an efficient and effective way to rapidly improve diabetes care. Diabetes. 48 (Suppl 1):470A, 1999.

30. Champaigne N, Edelman SV. Long term improvement in attitude, exercise routine, and maintenance of glucose in type I diabetes following attendance in an intensive educational and motivational program. Diabetes. 48 (Suppl 1):38A, 1999.

31. Edelman SV, Pitzer KR, Desai S, Dunn TC, Yalia J. Detection of hypoglycemia and hyperglycemia using the GlucoWatch Biographerâ. Diabetes. 49 (Suppl 1):420P, 2000.

32. Edelman SV, Bell JM, Champaigne N, Serrano RB. Weekly home testing of fructosamine improves glycemic control. Diabetes. 49 (Suppl 1):421P, 2000.

33. Champaigne N, Serrano RB, Edelman SV. Patient's perception of care: differences between a diabetes specialist and general practitioners. Diabetes. 49 (Suppl 1):1357P, 2000.

34. Kieren JM, Laakso M, Edelman SV, Hook G, Baron AD. Physiologic coupling of skeletal muscle metabolism and blood flow. Diabetes. 49 (Suppl 1):1840PO, 2000.

35. Epshteyn VA, Morrison K, Krishnaswamy P, Kazanegra R, Maisel AS, Henry R, Edelman SV. Screening patients with diabetes mellitus for cardiac dysfunction using B-natriuretic peptide (BNP). Diabetes. (Suppl 2):145OR, 2001.

36. Champaigne N, Squibb SM, Edelman SV. Improving diabetes care at the community level through education, motivation and self-advocacy: Diabetes. (Suppl 2):800P, 2001.

37. Cefalu WT, Beatty JD, Fisher JC, Edelman SV. Long-term continous glucose monitor in subcutaneous tissue: accuracy results from a 25-subject study. Diabetes. (Suppl 2):47OR, 2002.

38. Edelman SV, Bouvet M, Fisher JC, Cefalu W. Glucose sensor in the subcutaneous tissue: continuous data in patients with type 1 diabetes. Diabetes. (Suppl 2):48OR, 2002.

39. Morrison KL, Maisel AS, Epshteyne VA, Henry RR, Mudaliar S, Edelman SV. The use of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes mellitus. Diabetes. (Suppl 2):691P, 2002.

40. Cefalu, W.T., Beatty, David, Fisher, Jack C., Edelman, S.V. Long-Term Continuous Glucose Monitor in Subcutaneous Tissue: Accuracy Results from a 25-Subject Study. Diabetes. 51 (Suppl 2): 47-OR, 2002.

41. Edelman, SV, Bouvet, M., Fisher, Jack, Cefalu, William. Glucose Sensor in the Subcutaneous Tissue: Continuous Data in Patients with Type 1 Diabetes. Diabetes. 51 (Suppl 2): 48-OR, 2002.

42. Brauker J, Goode P, Carr-Brendel V, Henry R, Edelman SV. Use of continuous glucose monitoring alerts to better predict, prevent and treat post prandial hyperglycemia. Diabetes. 52 (Suppl 1):388P, 2003.

43. Edelman S, Henry R, Polonsky B, Benci R, Platt C. Differences in characteristics between people with type 2 diabetes who use the internet for health information compared to non-diabetics using a large 2 million-person database. Diabetes. 52 (Suppl 1):1119P, 2003.

44. Polonsky W, Fisher L, Dowe S, Edelman S. Why do patients resist insulin therapy? Diabetes. 52 (Suppl 1):1811P, 2003.

45. Brauker, J, Goode, P, Carr-Brendel, Victoria, Henry, R, Edelman, SV. Use of continuous glucose monitoring alerts to better predict, prevent and treat Post Prandial Hyperglycemia. Diabetes. 52 (Suppl 1):388P, 2003.

46. Edelman, SV, Henry, R, Polonsky, B, Benci, R, Platt, C. Differences in characteristics between people with Type 2 Diabetes who use the Internet for health information compared to non-diabetics using a large 2 million person database. Diabetes. 52 (Suppl 1): 11119P. 2003.

47. Polonsky, W, Fisher, L, Dowe, S, Edelman, S. Why do patients resist insulin therapy? Diabetes. 52 (Suppl 1): 1811P, 2003.

48. Shah, J., Kirkman, S., Wendell, C., McCarren, M., Duckworth, W., Abraira, C., The VADT Group, Edelman, S. Baseline Macrovascular Disease Correlates in Older Type 2 Diabetic Patients in U.S. Veterans Affairs Diabetes Trial.

49. Bhalla, MA, Chiang, A, Epshteyn, VA, Bhalla, V, Kazanegra, R. Clopton, P, Krishnaswamy, P, Morrison LK, Chiu, A, Gardetto, N, Mudaliar, S, Edelman, SV, Henry, RR, Maisel AS. Prognostic Rose of Brain Natriuretic Peptide (BNP) Levels in Patients with Type 2 Diabetes Mellitus. J Card Failure 10(4):S48 #111. 8th Annual Scientific Meeting of the Heart Failure Society of America, 2004.

50. Scott RS, Morrison Z, Edelman S, Garg SK. Early detection of hyper and hypoglycemic excursions in subjects with type 1 diabetes using a long-term continuous glucose sensor. Submitted April 2004.

51. Edelman S, Beh, G. Changes in Self-care Behavior and Improved Glycemic Control in People with Diabetes after Attending an Intensive Educational and Motivational Conference. Submitted January 2005.

52. Bergenstal, RM, Johnson, ML, Anderson, RL, Edelman, S, Kendall, DM. Impact of a One-Day Diabetes Education Program on Glycemic Control. Submitted January 2005.

53. Edelman, S, Polonsky, WH, Beh, G. Changes in Self-Care Behavior and Improved Glycemic Control in People with Diabetes after Attending an Intensive Educational and Motivational Conference. Diabetes. 54 (Suppl 1): 299OR, 2005.

54. Bergenstal, RM, Johnson, ML, Anderson, RL, Edelman, S, Kendall, DM. Impact of a One-Day Diabetes Education Program on Glycemic Control. Diabetes. 54 (Suppl 1): 939P, 2005.

55. Aroda, V, Edelman, S, Kruger, D, Chen, K, Lush, C, Halseth, A, Wang, Y, Burns, C, Weyer, C. Perceptions of Appetite and Weight Control Associated with Weight Loss in Pramlintide-Treated Obese Subjects. Accepted for publication.

55. Weyer, C, Fujioka, K, Aroda, V, Edelman, S, Chen, K, Lush, C, Wang, Y, Burns, C, Lutz, K, McIntyre, S, Kornstein, J, Wintle, M, Baron, A. Safety, Dose-Tolerance and Weight-Related Effects of Pramlintide in Obese Subjects with or without Type 2 Diabetes.

56. Villa-Caballero, L, Huey, R, Diaz-Redondo, A, Polonsky, W, Palinkas, L, Edelman, S. Ethnic Differences in Complementary and Alternative Medicine Use Among Patients with Diabetes. Diabetes. Submitted January 2006.

57. Isley, W, Edelman, S, Schwartz, S, Fonseca, V, Mudaliar, S, Skouse, J, Ryan, T, Henry, R. Very Low Dose Glucagon Insulin Induced Hypoglycemia in Patients with Type 1 Diabetes. Accepted for Publication Diabetes.

Audio Publications:

1. Edelman SV. The implantable pump in type II patients. New developments in diabetes. Audio Digest Internal Medicine 4:11, 1993.

2. Edelman SV. New advances on diabetes. Audio-Digest Internal Medicine 48:16, 2001.

3. Edelman SV. New perspectives in diabetes Audio-Digest Internal Medicine 50:07, 2003

Television/Video Productions

1. Taking Control of Your Diabetes: Artisan Productions, 1995.

2. Therapy of Type II Diabetes: Sam and Rose Stein Institute for Aging, 1995.

3. Type II Diabetes: Controlling Glucose and Outcomes: Veterans Affairs Satellite Program, 1995.

4. Taking Control of Your Diabetic Feet An Easy and Essential Task: Artisan Productions, 1996.

5. Prevention of Diabetes: Channel 10 Midday News, San Diego, September 24, 1996.

6. Adult-Onset Diabetes: Channel 8 Morning News, San Diego, November 20, 1996.

7. Taking Control of Your Diabetes: UCSD Public Television Channel 35. San Diego California, October 16, 1997.

8. Insulin is Essential for Life: The Steve Edelman story, Eli Lilly National Sale Mtg. 1998.

9. Diabetes Dialogue: Advice for Life, VHA Broadcasting System. November 12, 1998.

10. Diabetes Dialogue: Living Smarter, Feeling Better, VHA Broadcasting System. 1999.

11. New, Less Painful Testing Procedure Officers Hope for Controlling Diabetes: Lifescan, December 29, 2000.

12. Medical Management of Type II Diabetes: Drs. Robbins, Caplan & Edelman, 2000.

13. Advancements in Insulin Therapy: Eli Lilly, 2000.

14. Taking Control of Your Diabetes: MDTV Tape #9801012, 2000.

15. The Latest Developments in Diabetes Research and Treatment: OneTouch Diabetes Update, Lifescan, 2001.

16. Diabetes and the underserved population. Discovery Health Channel, 2002. Edge of a Dream Productions.

17. Diabetes Dialog: Insulin Therapy for people with Type 2 diabetes. VHA Broadcasting System, 2003.

18. Closing the Gap in Type 2 Diabetes: The Primary Care Perspective. University of Wisconsin & INCE, 2003.

19. Disease Progression of Type 2 Diabetes: Med Cases, 2004.

20. Progress in Caring for Diabetics: Emerging Treatment Options. The Caring for Diabetics Educational Forum, International Medical Press, Lilly, 2004.

21. Living with Diabetes These Days: KPBS, 2004.

22. Changing Course: Diagnosing & Treating Type II Diabetes. University of North Texas Health Science Center at Fort Worth. 2005.

23. Application of Technology to Diabetes Management: Opportunities for Physicians and their patients using Pattern Management as an integral part of patient care: Diabetes Care, Franklin Lakes, N.J. June 2004.